← Leaderboards
Dianhua Jiang
Cedars-Sinai Medical Center
$4,746,137
Attributed
$5,817,191
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $936.1K · FY2015–25$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,817,191 · 3
By mechanism
R01$3,716,640 · 2
P01$2,100,551 · 1
Top collaborators
- Paul Wesley Noble4 shared
Most similar at Cedars-Sinai Medical Center
Same institution · by research overlap
- Ekihiro Seki$13,011,862
- Sarah J Parker$4,415,288
Others in their field
Top investigators on “In Vitro”
- David Heimbrook · Leidos Biomedical Research, Inc.$553,787,942
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Dennis R. Burton · Scripps Research Institute$79,204,175
Research focus
In VitroEpithelial CellsPulmonary FibrosisPlayCellsIn VivoFibroblastsFibrosisBleomycinDepositionMolecularMesenchymalLungPhenotypeEpithelialTissuesLung InjuryAnimal ModelMouse ModelPublicationsLung DiseasesLung InflammationChronicImmune
Grant awards (11)
Targeting WNT7A Signaling in Pulmonary Fibrosis$787,266
R01 · FY2025 · HL · contact PI
Targeting WNT7A Signaling in Pulmonary Fibrosis$787,266
R01 · FY2024 · HL · contact PI
Mouse Models of Fibroproliferative Lung Disease$425,000
P01 · FY2022 · HL · contact PI
Mouse Models of Fibroproliferative Lung Disease$425,000
P01 · FY2021 · HL · contact PI
Mouse Models of Fibroproliferative Lung Disease$425,000
P01 · FY2020 · HL · contact PI
Mouse Models of Fibroproliferative Lung Disease$425,000
P01 · FY2019 · HL · contact PI
Targeting beta-arrestins in Pulmonary Fibrosis$535,527
R01 · FY2018 · HL · contact PI
Mouse Models of Fibroproliferative Lung Disease$400,551
P01 · FY2018 · HL · contact PI
Targeting beta-arrestins in Pulmonary Fibrosis$535,527
R01 · FY2017 · HL · contact PI
Targeting beta-arrestins in Pulmonary Fibrosis$535,527
R01 · FY2016 · HL · contact PI
Targeting beta-arrestins in Pulmonary Fibrosis$535,527
R01 · FY2015 · HL · contact PI